Ekström Eva-Charlotte, Hyder S M Ziauddin, Chowdhury A Mushtaque R, Chowdhury Sadia A, Lönnerdal Bo, Habicht Jean-Pierre, Persson Lars Ake
Epidemiology Division, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Am J Clin Nutr. 2002 Dec;76(6):1392-400. doi: 10.1093/ajcn/76.6.1392.
According to our current understanding, iron absorption with weekly iron supplements is not higher than that with daily supplements (ie, there is no mucosal block). However, community-based trials have repeatedly shown that a weekly regimen is as effective as a daily one. Furthermore, when differences in absorption are found, they are commonly smaller than would be expected on the basis of differences in the amount of iron provided. The possibility of differential compliance between the regimens needs to be evaluated to explain these findings.
Taking compliance into account, we compared the efficacy and trial effectiveness of weekly and daily iron supplementation during pregnancy.
In Bangladesh, 50 antenatal centers were randomly assigned to prescribe either 2 doses of 60 mg Fe once weekly or 1 dose of 60 mg Fe/d. Compliance was monitored by using a pill bottle equipped with an electronic counting device. Hemoglobin concentrations were measured at baseline and after 4, 8, and 12 wk of supplementation.
There was no differential effect per iron tablet between weekly and daily regimens. A 12-wk daily regimen (68% compliance) produced a small but significantly greater hemoglobin response than did the weekly regimen (104% compliance). The first 20 tablets consumed produced most of the effect; after 40 tablets, there was no further response.
There was no evidence of a mucosal block in the daily regimen. Over 12 wk, 50% of the amount of iron in a daily regimen was sufficient for maximum hemoglobin effect. The weekly regimen provided a large part of this amount, explaining the limited difference in effect. It appears that the current international recommendation for iron supplementation in pregnancy is higher than necessary.
根据我们目前的认识,每周补铁时铁的吸收并不高于每日补铁(即不存在黏膜阻滞)。然而,基于社区的试验反复表明,每周给药方案与每日给药方案效果相同。此外,当发现吸收存在差异时,其通常比基于所提供铁量的差异预期的要小。需要评估不同给药方案之间依从性差异的可能性,以解释这些发现。
考虑到依从性,我们比较了孕期每周和每日补铁的疗效及试验效果。
在孟加拉国,50个产前保健中心被随机分配,分别开具每周2剂60毫克铁或每日1剂60毫克铁的处方。通过使用配备电子计数装置的药瓶监测依从性。在基线时以及补铁4周、8周和12周后测量血红蛋白浓度。
每周和每日给药方案每片铁剂的效果无差异。每日给药12周方案(依从率68%)产生的血红蛋白反应虽小但显著大于每周给药方案(依从率104%)。服用的前20片药产生了大部分效果;服用40片药后,不再有进一步反应。
每日给药方案中没有黏膜阻滞的证据。在12周内,每日给药方案中铁含量的50%足以产生最大血红蛋白效应。每周给药方案提供了该量的很大一部分,这解释了效果差异有限的原因。看来目前国际上关于孕期补铁的建议高于必要水平。